The new therapeutic options like lomitapide and ANGPTL3-inhibitors appear to be successful in treating adult hoFH patients, but are currently of limited use in pediatric patients, since side effects and missing drug approval have to be considered. The gene discussed is ANGPTL3; the disease is homozygous familial hypercholesterolemia.